Press releases

Orchard Therapeutics announces extension of its collaboration with Manchester University to include Sanfilippo Syndrome type B

Orchard Therapeutics Limited, announces today that it has acquired an exclusive license to develop lentivirus-based autologous ex-vivo gene therapy for Sanfilippo syndrome type B (or MPS-IIIB) from The University of Manchester, UK

Read more

Bringing next-generation gene therapy to the clinic

An interview of Dr. Andrea Spezzi by UCL Innovation Forum

Read more

Orchard Therapeutics announces that OTL-101 has received a designation as Promising Innovative Medicine by UK’s regulatory agency

Orchard Therapeutics Limited (“Orchard”), today announces that the UK Medicines and Healthcare Products Regulatory Agency (“MHRA”) granted a Promising Innovative Medicine Designation to OTL-101

Read more

Orchard Therapeutics appoints Mark Rothera as CEO

Orchard Therapeutics today announces the appointment of Mark Rothera as President and Chief Executive Officer

Read more

Orchard Therapeutics announces that OTL-101 has received a Rare Paediatric Disease Designation

The US Food and Drug Administration (FDA) granted a Rare Paediatric Disease Designation to OTL-101 for the treatment of adenosine deaminase severe combined immunodeficiency, commonly known as ADA-SCID or “bubble baby” disease

Read more